<SEC-DOCUMENT>0001193125-21-063569.txt : 20210301
<SEC-HEADER>0001193125-21-063569.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301162959
ACCESSION NUMBER:		0001193125-21-063569
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210301
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		21698270

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d320584d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20210301" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-03-01_to_2021-03-01">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-03-01_to_2021-03-01">0001055726</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ino-20210301.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-03-01_to_2021-03-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-03-01_to_2021-03-01">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt:datemonthdayyearen">March&#160;1, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-03-01_to_2021-03-01">Inovio Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-03-01_to_2021-03-01">001-14888</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-03-01_to_2021-03-01">33-0969592</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-03-01_to_2021-03-01">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-03-01_to_2021-03-01">Suite 110</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-03-01_to_2021-03-01">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-03-01_to_2021-03-01">PA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-03-01_to_2021-03-01">19462</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-03-01_to_2021-03-01">(267)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-03-01_to_2021-03-01">440-4200</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-03-01_to_2021-03-01">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-03-01_to_2021-03-01">INO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-03-01_to_2021-03-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;1, 2021, Inovio Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) issued a press release announcing its financial results for the fourth quarter and year ended December&#160;31, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. In accordance with General Instruction B.2. of Form <span style="white-space:nowrap">8-K,</span> the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any of the Company&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Securities Act</span></span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;1, 2021, the Company issued a press release announcing results from its ongoing Phase 3 clinical trial of its product candidate <span style="white-space:nowrap">VGX-3100</span> for the treatment of high-grade precancerous cervical dysplasia caused by <span style="white-space:nowrap">HPV-16</span> and/or <span style="white-space:nowrap">HPV-18.</span> A copy of this press release is furnished herewith as Exhibit 99.2 to this report. The information contained in the press release furnished as Exhibit 99.2 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any of the Company&#8217;s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d320584dex991.htm">Press Release, dated March&#160;1, 2021, &#8220;INOVIO Reports Fourth Quarter 2020 And <span style="white-space:nowrap">Year-End</span> Financial Results.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d320584dex992.htm">Press Release, dated March&#160;1, 2021, &#8220;INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating <span style="white-space:nowrap">VGX-3100,</span> its <span style="white-space:nowrap">DNA-based</span> HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by <span style="white-space:nowrap">HPV-16</span> and/or <span style="white-space:nowrap">HPV-18.&#8221;</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover page interactive data file (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">INOVIO PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;1, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Peter Kies</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d320584dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320584g0302005608426.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INOVIO Reports Fourth Quarter 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>And <FONT STYLE="white-space:nowrap">Year-End</FONT> Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Investor Call Today at 4:30 PM ET </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">PLYMOUTH
MEETING, PA &#150; March&nbsp;1, 2021 &#150; INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and <FONT
STYLE="white-space:nowrap">HPV-associated</FONT> diseases, today reported financial results for the quarter ended December&nbsp;31, 2020. INOVIO&#146;s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today
to discuss financial results and provide a general business update, including: <FONT STYLE="white-space:nowrap">top-line</FONT> efficacy data from REVEAL 1; a Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">VGX-3100;</FONT> a progress
update for the company&#146;s INNOVATE Phase 2/3 <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine clinical trial and its development strategy regarding the new <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine addressing the current
and future COVID variants of concern (VOC); and a general update on its DNA medicines platform. The live webcast and a replay may be accessed by visiting INOVIO&#146;s website at
<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/events-and-presentations/default.aspx</FONT></FONT></U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>INOVIO Fourth
Quarter and <FONT STYLE="white-space:nowrap">Year-End</FONT> 2020 Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">On March&nbsp;1, 2021, INOVIO announced that it met primary and secondary efficacy endpoints among all evaluable
subjects for the REVEAL 1 (<B><U>R</U></B>andomized <B><U>E</U></B>valuation of <B><U>V</U></B><FONT STYLE="white-space:nowrap">GX-3100</FONT> <B><U>a</U></B>nd <B><U>E</U></B>lectroporation for the treatment of Cervical HSI<B><U>L</U></B>) trial.
This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials evaluating the safety, tolerability and efficacy of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> to treat <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> cervical high-grade squamous intraepithelial lesions (HSIL) using the company&#146;s proprietary
CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 5PSP device. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In first quarter 2021, INOVIO completed enrollment of 400 subjects in the Phase 2 segment of the INNOVATE
(<B><U>IN</U></B>OVIO I<B><U>NO</U></B>-4800 <B><U>Va</U></B>ccine <B><U>T</U></B>rial for <B><U>E</U></B>fficacy) Phase 2/3 clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">INOVIO is addressing the new COVID variants through evaluating the impact of newly circulating strains of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus on the immune profile of the <FONT STYLE="white-space:nowrap">INO-4800</FONT> vaccine and developing next-generation,
<FONT STYLE="white-space:nowrap">pan-COVID</FONT> vaccine candidates whose design could potentially provide better protection against the known and currently unknown
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SAR-CoV-2</FONT></FONT> variants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In December, Phase 1 peer-reviewed clinical data from the first cohort of 40 participants administered with <FONT
STYLE="white-space:nowrap">INO-4800</FONT> was published in The Lancet&#146;s <I>EClinicalMedicine</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In November, INOVIO presented overall survival at 18 months (OS18) data from its novel combination trial of <FONT
STYLE="white-space:nowrap">INO-5401</FONT> and <FONT STYLE="white-space:nowrap">INO-9012</FONT> in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor Libtayo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> at the
Society for Neuro-Oncology (SNO) 2020 Annual Meeting. Median overall survival among the unmethylated Glioblastoma Multiforme<B> </B>(GBM) patients in the trial was 17.9 months, which compares favorably to historical controls. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;J. Joseph Kim, INOVIO&#146;s President and CEO, said, &#147;We have had a productive fourth
quarter across our DNA medicines platform, including significant developments within both our HPV and oncology programs. We presented encouraging clinical efficacy results in a landmark combination trial for
<FONT STYLE="white-space:nowrap">INO-5401</FONT> in GBM at the SNO 2020 Annual Meeting last November. Most importantly, we announced that our REVEAL 1 Phase 3 clinical trial for <FONT STYLE="white-space:nowrap">VGX-3100</FONT> met primary and
secondary endpoints among all evaluable subjects. We are truly proud to advance <FONT STYLE="white-space:nowrap">VGX-3100</FONT> as the first DNA medicine to reach this important milestone.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#147;INOVIO recognizes and applauds the incredible work to address the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic across the
industry, while also acknowledging the need for continued collaboration and coordination in vaccine development, manufacturing and distribution. I am also extremely proud of the dedication and efforts of our INOVIO team in contributing to this
global endeavor, grateful for the continued support of our partners, and thankful for all Phase 2 participants in our INNOVATE clinical trial for their help in the ongoing fight against the pandemic. We look forward to successfully completing our
Phase 2 segment in the second quarter and seeking to advance to the Phase 3 portion of the trial.&#148;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>INOVIO Fourth Quarter 2020
Program Updates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>DNA Immunotherapies: <FONT STYLE="white-space:nowrap">HPV-associated</FONT> Diseases and Immuno-Oncology </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U><FONT STYLE="white-space:nowrap">HPV-related</FONT> Diseases </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">VGX-3100:</FONT> Cervical, Vulvar, and Anal HSIL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO announced today that it met primary and secondary endpoints
among all evaluable subjects for the REVEAL 1 trial. The trial protocol-defined modified intention to treat (mITT) population (N=193) includes all subjects with endpoint data. For the primary endpoint of histopathological regression of HSIL combined
with virologic clearance of <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18</FONT> at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo
group (p=0.022; 12.4% difference in percentage, 95%CI: 0.4,22.5), thus achieving statistical significance. All secondary efficacy endpoints were achieved in the mITT population. These endpoints were: a) regression of cervical HSIL to normal tissue
combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The trial protocol-defined intention to treat (ITT) population (N=201) includes all randomized subjects regardless of availability of endpoint data and
defines those without endpoint data as <FONT STYLE="white-space:nowrap">non-responders.</FONT> There were eight such subjects (seven in the treatment group, one in the placebo group). Including subjects with missing endpoint data, the percentage of
subjects meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 11.4% difference in percentage, 95%CI: <FONT STYLE="white-space:nowrap">-0.4,21.2),</FONT> which was not
statistically significant. All secondary endpoints were achieved in the ITT population except for regression of cervical HSIL alone (12.8% difference in percentage, 95%CI: <FONT STYLE="white-space:nowrap">-0.6,24.5).</FONT> The reasons for missing
endpoint data were: one subject was randomized but was never dosed, one withdrawal due to pregnancy, one withdrawal due to administration error, one withdrawal due to post-administration pain, one loss of
<FONT STYLE="white-space:nowrap">follow-up</FONT> due to COVID19-related travel restrictions, and three losses to <FONT STYLE="white-space:nowrap">follow-up</FONT> due to undetermined reasons. A <FONT STYLE="white-space:nowrap">per-protocol</FONT>
analysis will also be performed upon trial completion. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">There were no treatment-related serious adverse events and most adverse events were self-resolving and
were considered to be mild to moderate, consistent with earlier clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">REVEAL 1 and REVEAL 2 are designed to assess and confirm the
safety, tolerability, immunogenicity, and efficacy of <FONT STYLE="white-space:nowrap">VGX-3100.</FONT> INOVIO will continue to follow subjects in REVEAL 1 for safety and durability of response for 18 months following the last administration and
REVEAL 2 is currently enrolling subjects. INOVIO expects to present REVEAL 1 findings at a scientific meeting this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In December 2020, the
company reported positive Phase 2 efficacy results demonstrating that <FONT STYLE="white-space:nowrap">VGX-3100</FONT> showed resolution of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT>
precancerous anal HSIL in 50% (11 of 22) of subjects six months following the start of treatment. The open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> trial also showed <FONT STYLE="white-space:nowrap">VGX-3100</FONT> to be
well-tolerated in treating men and women with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-/18-associated</FONT></FONT></FONT> anal HSIL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In January 2021, the company also reported positive efficacy results from an open-label Phase 2 trial of
<FONT STYLE="white-space:nowrap">VGX-3100</FONT> to treat <FONT STYLE="white-space:nowrap">HPV-16</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-18-associated</FONT></FONT> vulvar HSIL. A 25% or more reduction in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> vulvar HSIL was observed for 63% of trial participants (12 of 19) treated with <FONT STYLE="white-space:nowrap">VGX-3100</FONT> at six months
post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no <FONT STYLE="white-space:nowrap">HPV-16/18</FONT> virus detectable in the healed area. By comparison, the spontaneous resolution of
vulvar HSIL caused by <FONT STYLE="white-space:nowrap">HPV-16/18</FONT> is estimated to be 2%. The trial also showed <FONT STYLE="white-space:nowrap">VGX-3100</FONT> to be well-tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO will continue to evaluate expansion of indications for vulvar and anal dysplasia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">INO-3107:</FONT> Recurrent Respiratory Papillomatosis (RRP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In November, INOVIO dosed its first subject with DNA medicine <FONT STYLE="white-space:nowrap">INO-3107</FONT> in a Phase 1/2 clinical trial for the
treatment of RRP. The trial, called <FONT STYLE="white-space:nowrap">RRP-001,</FONT> is a clinical trial investigating the efficacy, safety, tolerability and immunogenicity of INOVIO&#146;s novel <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">HPV-6/HPV-11</FONT></FONT> therapy in subjects with RRP, designed to eradicate both the cause, and sequelae, of infection of the airway with HPV in subjects who have required at least two surgical interventions per year
for the past three years for the removal of associated papilloma(s). For this study, adult subjects will first undergo surgical removal of their papilloma(s) and then receive four doses of <FONT STYLE="white-space:nowrap">INO-3107,</FONT> once every
three weeks. The primary efficacy endpoint is a doubling or more in the time between surgical interventions following the first dose of <FONT STYLE="white-space:nowrap">INO-3107</FONT> relative to the frequency prior to study therapy. The study is
currently open in the United States and is listed on ClinicalTrials.Gov (NCT04398433). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Immuno-oncology </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">INO-5401:</FONT> Newly Diagnosed GBM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">At the SNO 2020 Annual Meeting last November, INOVIO presented data from the company&#146;s novel combination trial of DNA medicines <FONT
STYLE="white-space:nowrap">INO-5401</FONT> and <FONT STYLE="white-space:nowrap">INO-9012</FONT> in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor Libtayo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (cemiplimab)
in the treatment of newly diagnosed GBM. In the MGMT promoter unmethylated cohort, which is the more difficult to treat group, 19/22 (86%) subjects had an <FONT STYLE="white-space:nowrap">IFN-gamma</FONT> T cell response that increased over baseline
to one or more of the antigens encoded by <FONT STYLE="white-space:nowrap">INO-5401.</FONT> In the MGMT promoter methylated cohort, 16/17 (94%) subjects had an <FONT STYLE="white-space:nowrap">IFN-gamma</FONT> response that increased over baseline
to one or more of the antigens encoded by <FONT STYLE="white-space:nowrap">INO-5401.</FONT> The novel combination of <FONT STYLE="white-space:nowrap">INO-5401</FONT> + <FONT STYLE="white-space:nowrap">INO-9012</FONT> continues to demonstrate a
well-tolerated safety profile when given not only with radiation and chemotherapy, but also with <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade by Libtayo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which is being jointly
developed by Regeneron and Sanofi. Additional data will be provided in the coming months, including correlative immunology and tissue data, as well as additional patient survival data. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U><FONT STYLE="white-space:nowrap">INO-4800:</FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT> DNA Vaccine
Candidate </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>Phase 1 Update and Publication </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In
December 2020, Phase 1 clinical data from the first cohort of 40 participants for <FONT STYLE="white-space:nowrap">INO-4800</FONT> was published in The Lancet&#146;s <I>EClinicalMedicine</I> in a paper, titled &#147;Safety and immunogenicity of <FONT
STYLE="white-space:nowrap">INO-4800</FONT> DNA vaccine against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2:</FONT></FONT> a preliminary report of an open-label, Phase 1 clinical trial.&#148; The trial found that <FONT
STYLE="white-space:nowrap">INO-4800</FONT> was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4 and CD8 T cells). Key findings from
the trial included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The 1.0 mg and 2.0 mg dose group both demonstrated seroconversion in 95% of the subjects, with 78% demonstrating
neutralizing antibodies in the 1.0 mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg dose group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Cellular (T cell) responses were observed against multiple regions of the spike protein, including the RBD region. 74%
had measurable cellular responses at the 1.0 mg dose group and 100% of the subjects in the 2.0 mg dose group demonstrated cellular responses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Through week 8, no serious adverse events were reported. Only 6 related Grade 1 adverse events in 5 subjects were
observed, primarily mild injection site reactions (e.g., redness); none of these increased in frequency with the second administration. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>Phase
2 Update </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">After the quarter, INOVIO completed enrollment of 400 subjects in the Phase 2 segment of the INNOVATE clinical trial. The U.S.
Department of Defense (DoD) has committed to provide funding for both the Phase 2 and Phase 3 segments of the INNOVATE clinical trial, in addition to the $71.1&nbsp;million of funding previously announced in June 2020 for the large-scale manufacture
of the company&#146;s proprietary smart device CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP, production of doses and the procurement of CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 2000 devices.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>License Agreement for Greater China with Advaccine </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO also entered into a collaboration and license agreement for <FONT STYLE="white-space:nowrap">INO-4800</FONT> with Advaccine, who will have the
exclusive right to develop, manufacture and commercialize <FONT STYLE="white-space:nowrap">INO-4800</FONT> within Greater China, which includes Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will license its plasmid manufacturing process
for use with <FONT STYLE="white-space:nowrap">INO-4800</FONT> and other INOVIO pipeline product candidates to INOVIO with the right to sublicense to INOVIO&#146;s manufacturing partners. INOVIO received an upfront payment of $3.0&nbsp;million and is
eligible to receive up to an aggregate of $108.0&nbsp;million upon the achievement of specified development and sales-based milestones for <FONT STYLE="white-space:nowrap">INO-4800</FONT> in Greater China. INOVIO is entitled to receive a royalty
equal to a high single-digit percentage of annual net sales in each region within Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>INOVIO&#146;s Strategy to Address New Variants of Concern (VOC)
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO has been closely monitoring the development and evolution of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> (which causes <FONT STYLE="white-space:nowrap">COVID-19)</FONT> mutations, with a particular focus on the UK, South African and Brazilian variants. With
instances of these variants on the rise globally and the UK variant expected to be the dominant strain in the United States by March, the emergence and the spread of the variants have been an area of high priority for INOVIO. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><U>INOVIO is addressing the VOC through a <FONT STYLE="white-space:nowrap">two-pronged</FONT> approach: </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">INOVIO is currently evaluating the impact of newly circulating strains of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus on the immune profile of <FONT STYLE="white-space:nowrap">INO-4800</FONT> through an assessment of binding antibodies, neutralizing antibodies in both live and pseudo assays as well assessing
the impact of the <FONT STYLE="white-space:nowrap">INO-4800-generated</FONT> T cell responses on these variants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">INOVIO is also developing next-generation, <FONT STYLE="white-space:nowrap">pan-COVID</FONT> vaccine candidates that
could be tailored to the known and potentially unknown <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SAR-CoV-2</FONT></FONT> variants. Our next-generation <FONT STYLE="white-space:nowrap">pan-COVID</FONT> vaccine candidates
utilize our proprietary SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> gene optimization algorithm to analyze the available sequence data from all existing circulating variants and create a synthetic
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SAR-CoV-2</FONT></FONT> spike protein gene design intended to protect against the known VOC (notably the UK, SA and Brazilian strains) as well the future unknown strains.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s DNA vaccines are designed to mitigate the risk of the new viral variants through three main mechanisms: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Utilizing SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, INOVIO is able to rapidly design candidates
that have the potential to be protective against multiple newly emerging variants, which could result in a <FONT STYLE="white-space:nowrap">pan-variant</FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine solution. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">DNA vaccines generate a balanced immune response, including T cell responses, which could make them less susceptible to
changes in the genetic sequence of the virus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">DNA vaccines can be used for multiple boosts without being impacted by anti-vector immunity or an increase in
reactogenicity. Moreover, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials have shown that DNA vaccines could also be used safely and efficiently to boost the initial immune responses generated by multiple other
vaccine platforms. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">DNA-encoded</FONT> monoclonal antibody
(dMAb<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-</FONT></FONT> Innovative monoclonal antibody platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In December 2020, INOVIO announced that the company and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and
Indiana University received a $37.6&nbsp;million grant from DARPA, a research and development agency of the DoD and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), to use INOVIO&#146;s
innovative dMAb<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2-specific</FONT></FONT></FONT> dMAbs<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> which could offer versatile capabilities to function as both a therapeutic and preventive treatment for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Using our core DNA platform technology,
dMAbs<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are constructed by encoding the DNA sequence for a specific monoclonal antibody in a DNA plasmid. The plasmids are then directly delivered into cells of the body using CELLECTRA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> delivery devices, enabling these cells to manufacture the mAbs in vivo, unlike conventional mAb technology that requires manufacturing outside of the body. INOVIO&#146;s dMAbs<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> also offer a cost-effective treatment option, are fast to administer to subjects, can be quickly manufactured and scaled up compared to traditional recombinant monoclonal antibody-based
therapies, and do not require cold chain transport or storage. Notably, the overall approach can be applied beyond <FONT STYLE="white-space:nowrap">COVID-19</FONT> for any preventive and therapeutic treatment modalities, including infectious
disease, cancer, or any other disease that can be treated by recombinant monoclonal antibody-based therapies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><U>Fourth Quarter and Full Year 2020 Financial Results </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Total revenue was $5.6&nbsp;million and $7.4&nbsp;million for the quarter and year ended December&nbsp;31, 2020, respectively, compared to $279,000 and
$4.1&nbsp;million for the same periods in 2019, respectively. Total operating expenses were $34.9&nbsp;million and $131.5&nbsp;million for the quarter and year ended December&nbsp;31, 2020, respectively, compared to $30.7&nbsp;million and
$115.2&nbsp;million for the same periods in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s net loss for the quarter and year ended December&nbsp;31, 2020 was
$24.3&nbsp;million, or $0.14 per basic and diluted share, and $166.4&nbsp;million, or $1.07 per basic and diluted share, respectively, compared to net loss of $37.7&nbsp;million, or $0.38 per basic and diluted share, and $119.4&nbsp;million, or
$1.21 per basic and diluted share, for the quarter and year ended December&nbsp;31, 2019, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operating Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Research and development (R&amp;D) expenses for the quarter and year ended December&nbsp;31, 2020 were $26.3&nbsp;million and $94.2&nbsp;million,
respectively, compared to $22.0&nbsp;million and $88.0&nbsp;million, respectively, for the same periods in 2019. The year-over-year increase in R&amp;D expenses was primarily related to an increase in drug manufacturing expenses and outside services
related to <FONT STYLE="white-space:nowrap">INO-4800</FONT> and other clinical trials, an increase in engineering services related to our CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP device, higher device inventory
expense, an increase in consulting services related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> higher employee stock-based compensation expense due to increased staff numbers and an increase in patent maintenance and milestone fees to
Wistar. These increases were offset by an increase in contra-research and development expense recorded from grant agreements of $33.5&nbsp;million, among other variances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">General and administrative (G&amp;A) expenses were $8.6&nbsp;million and $37.2&nbsp;million, respectively, for the quarter and year ended
December&nbsp;31, 2020, versus $8.7&nbsp;million and $27.2&nbsp;million, respectively, for the same periods in 2019. The year-over-year increase in G&amp;A expenses was primarily related to an increase in legal expenses and employee and consultant <FONT
STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation, partially offset by a gain on foreign exchange among other variances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Capital Resources
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As of December&nbsp;31, 2020, cash and cash equivalents and short-term investments were $411.6&nbsp;million compared to $89.5&nbsp;million as of
December&nbsp;31, 2019. As of December&nbsp;31, 2020, the Company had 186.9&nbsp;million common shares outstanding and 203.0&nbsp;million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and
conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">On
January&nbsp;25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters&#146; discounts and
commissions and other estimated offering expenses, were $162.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s balance sheet and statement of operations are provided
below. Additional information is included in INOVIO&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, which can be accessed at: http://ir.inovio.com/financials/default.aspx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conference Call / Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss INOVIO&#146;s financial results and
provide a general business update. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The live webcast and a replay may be accessed by visiting INOVIO&#146;s website at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/events-and-presentations/default.aspx.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About INOVIO&#146;s DNA
Medicines Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and
infectious diseases, including coronaviruses associated with COVID-19 and MERS, for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA
medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO&#146;s proprietary hand-held
smart device called CELLECTRA<U><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></U>. The CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device uses a brief electrical pulse to reversibly open small pores in the cell
to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in
the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device is designed to ensure that the DNA medicine is efficiently delivered
directly into the body&#146;s cells, where it can go to work to drive an immune response. INOVIO&#146;s DNA medicines do not interfere with or change in any way an individual&#146;s own DNA. The advantages of INOVIO&#146;s DNA medicine platform are
how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical
trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious
diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and
tolerable immune response. INOVIO&#146;s lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for
70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers and a rare <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease,
recurrent respiratory papillomatosis (RRP); <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-HPV-related</FONT></FONT> cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine
development programs in coronaviruses associated with <FONT STYLE="white-space:nowrap">COVID-19</FONT> diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill<U></U>
&amp; Melinda Gates Foundation, Coalition for Epidemic </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
(JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of
Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of
Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information,
visit<U></U>&nbsp;<U>www.inovio.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CONTACTS: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Media: Jeff
Richardson, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> jrichardson@inovio.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Investors: Ben Matone, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> ben.matone@inovio.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA
medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical trials and the availability and timing of data from those studies and trials, and our
ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including
uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the
availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine
products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our
collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights
are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them,
the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report
on Form 10-K for the year ended December<U></U> 31, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed,
manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking
statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INOVIO Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,728,118</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,196,097</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,914,935</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,338,017</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,559,967</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,073</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts receivable from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">503,782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,332,044</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,357,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584,598</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,432</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,050,140</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">471,170,690</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,200,969</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fixed assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,348,144</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,773,017</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investment in affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,460,366</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,315,356</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investment in Geneos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,387</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,146,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,693,851</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,513,371</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,513,371</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,741,296</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,783,009</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,957,448</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,672,024</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">539,772,472</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,951,597</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,203,808</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,237,258</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable and accrued expenses due to affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">642,969</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">729,729</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,950,345</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,049,727</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,628</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,353</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred revenue from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,775</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,329,394</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,074,842</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant funding liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,474,310</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,065,212</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant funding liability from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">708,425</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,705,954</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,989,321</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,214</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,567</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible senior notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,139,988</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,180,325</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,515,834</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,842,592</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,819,023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,063,515</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,409,922</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,046</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,046</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Grant funding liability from affiliated entity, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,663</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,943</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,631,714</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,546,739</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Inovio Pharmaceuticals, Inc. stockholders&#146; equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock&#151;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at
December&nbsp;31, 2020 and 23 at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock&#151;par value $0.001; Authorized shares: 600,000,000 at December&nbsp;31, 2020 and
December&nbsp;31, 2019, issued and outstanding: 186,851,493 at December&nbsp;31, 2020 and 101,361,034 at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,851</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,361</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,367,406,869</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">742,646,785</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(906,196,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(739,785,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">472,608</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total Inovio Pharmaceuticals, Inc. stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,140,758</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,435,099</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,969,759</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,140,758</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,404,858</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">539,772,472</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,951,597</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INOVIO Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue under collaborative research and development arrangements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,170,586</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,636,945</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,860,785</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue under collaborative research and development arrangements from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,453,730</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,649</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449,524</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">786,904</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,536</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171,588</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other revenue from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,411,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,111,930</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,481,897</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,245,436</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,017,319</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,257,876</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,247,828</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,203,156</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,315,159</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,493,264</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,220,475</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,573,035</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124,082,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,108,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94,091,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,311,846</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,605,981</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,264,747</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,702,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,948,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360,795</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,670,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,763,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain (loss) on investment in affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,556,658</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,090,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,988,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,695,497</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(704,896</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,343,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on deconsolidation of Geneos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,121,075</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on extinguishment of convertible bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,177,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on extinguishment of convertible senior notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,762,030</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net loss before income tax benefit/(provision for income tax)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(162,890,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(120,809,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94,798,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257,335</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,169,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Share in net loss of Geneos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,584,610</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(167,474,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(120,551,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(96,967,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,063,757</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,192,558</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net loss attributable to Inovio Pharmaceuticals, Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,411,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119,359,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(96,967,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Weighted average number of common shares outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,126,857</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,717,999</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,539,997</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d320584dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g320584g0302010349590.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INOVIO Announces Positive Results from REVEAL 1, a </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Phase 3 Pivotal Trial Evaluating <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> its <FONT STYLE="white-space:nowrap">DNA-based</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>HPV Immunotherapy for the Treatment of High-grade </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Precancerous Cervical Dysplasia Caused by <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">HPV-18</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind,
placebo-controlled trial. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I><FONT STYLE="white-space:nowrap">VGX-3100</FONT> is the first DNA medicine to achieve efficacy endpoints in a Phase
3 clinical trial </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>INOVIO also continues to partner with QIAGEN to develop a <FONT STYLE="white-space:nowrap">pre-treatment</FONT> predictive
biomarker with the goal of identifying women expected to respond to <FONT STYLE="white-space:nowrap">VGX-3100</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Management to host a
live conference call today at 4:30 P.M. ET </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">PLYMOUTH MEETING, PA, March&nbsp;1, 2021 &#151; INOVIO, (NASDAQ:INO), a biotechnology company
focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, today announced it met primary and secondary endpoints
among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> to treat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> cervical high-grade squamous intraepithelial lesions (HSIL) using the company&#146;s proprietary
CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 5PSP device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The trial protocol-defined modified intention to treat (mITT)
population (N=193) includes all subjects with endpoint data. For the primary endpoint of histopathological regression of HSIL combined with virologic clearance of <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or
<FONT STYLE="white-space:nowrap">HPV-18</FONT> at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 12.4% difference in percentage, 95%CI: 0.4,22.5), thus achieving
statistical significance. All secondary efficacy endpoints were achieved. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical
HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The trial protocol-defined intention to treat (ITT) population (N=201) includes all
randomized subjects regardless of availability of endpoint data and defines those without endpoint data as <FONT STYLE="white-space:nowrap">non-responders.</FONT> There were eight such subjects (seven in the treatment group, one in the placebo
group). Including subjects with missing endpoint data, the percentage of subjects meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 11.4% difference in percentage, 95%CI: <FONT
STYLE="white-space:nowrap">-0.4,21.2),</FONT> which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (12.8% difference in percentage, 95%CI:
<FONT STYLE="white-space:nowrap">-0.6,24.5).</FONT> The reasons for missing endpoint data were: one subject was randomized but was never dosed, one withdrawal due to pregnancy, one withdrawal due to administration error, one withdrawal due to
post-administration pain, one loss of <FONT STYLE="white-space:nowrap">follow-up</FONT> due to COVID19-related travel restrictions, and three losses to follow up due to undetermined reasons. A <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT
STYLE="white-space:nowrap">per-protocol</FONT> (PP) analysis will also be performed upon trial completion. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">There were no treatment-related serious adverse events and most adverse events were self-resolving and
were considered to be mild to moderate, consistent with earlier clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">REVEAL 1 and REVEAL 2 are designed to assess and confirm the
safety, tolerability, and efficacy of <FONT STYLE="white-space:nowrap">VGX-3100.</FONT> INOVIO will continue to follow subjects in REVEAL 1 for safety and durability of response for 18 months following the last administration and REVEAL 2 is
currently enrolling subjects. INOVIO expects to present REVEAL 1 findings at a scientific meeting this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;J. Joseph Kim, President and
CEO of INOVIO, said, &#147;INOVIO is really proud to advance <FONT STYLE="white-space:nowrap">VGX-3100</FONT> as the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial in all evaluable subjects. We expect <FONT
STYLE="white-space:nowrap">VGX-3100,</FONT> if approved, to be an important therapeutic option for those impacted by
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-/18-related</FONT></FONT></FONT> disease. The REVEAL 1 efficacy and safety data also represent an important <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-platform</FONT></FONT> for INOVIO&#146;s DNA medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Mark Einstein, MD, MS, FACS, FACOG, Principal
Coordinating Investigator for the REVEAL 1 trial, said, &#147;There is a very significant need for a <FONT STYLE="white-space:nowrap">non-surgical</FONT> therapeutic for young women suffering from
<FONT STYLE="white-space:nowrap">HPV-associated</FONT> cervical dysplasia. These results are very encouraging and show that we are headed in the right direction.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Prakash Bhuyan, MD, PhD, Senior Vice President and Head of HPV Therapeutic Clinical Development at INOVIO, said, &#147;We thank the
investigators, site personnel, and patients who made this research possible. We are excited to be developing a new therapeutic designed to advance women&#146;s health. Through our ongoing partnership with QIAGEN, we also plan to develop
complementary a biomarker diagnostic test that would enable practitioners to more effectively identify women expected to respond to <FONT STYLE="white-space:nowrap">VGX-3100.&#148;</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biomarker Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In the course of the REVEAL 1 and
REVEAL 2 clinical trials, INOVIO continues to pursue development of a <FONT STYLE="white-space:nowrap">pre-treatment</FONT> <FONT STYLE="white-space:nowrap">RNA-based</FONT> biomarker blood test which could be used to identify prospective <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> patients who would be most likely to respond to the immunotherapy. INOVIO believes this will be an important element of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> product and market development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO announced in February that it is continuing its partnership with QIAGEN to <FONT STYLE="white-space:nowrap">co-develop</FONT> an <FONT
STYLE="white-space:nowrap">in-vitro</FONT> diagnostic based on RNA sequencing technology to guide clinical decision-making for the use of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> in cervical HSIL. This technology had previously been employed
in a <FONT STYLE="white-space:nowrap">post-hoc</FONT> assessment of VGX-3100 Phase 2 data by INOVIO, in which 85% of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> treated subjects who had the biomarker experienced regression of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-18-associated</FONT></FONT> cervical HSIL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">VGX-3100</FONT> REVEAL 1 Phase 3 Cervical Dysplasia Trial Design&nbsp;&amp; Highlights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Trial participants included 201 women, 18 years of age or older, who have histologically-confirmed cervical HSIL
associated with <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18,</FONT> but who were otherwise healthy. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:ARIAL" ALIGN="justify">(ClinicalTrials.gov Identifier: NCT03185013) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Participants received either <FONT STYLE="white-space:nowrap">VGX-3100</FONT> or placebo at 0, 4 and 12 weeks
(randomized 2:1). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Trial had 90% statistical power <FONT STYLE="white-space:nowrap">(two-sided</FONT> 0.05 alpha-level) for the evaluation
of the primary endpoint </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Results are based on the demonstration of having no evidence of HSIL associated with
<FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18</FONT> from cervical biopsy samples and <FONT STYLE="white-space:nowrap">non-detectability</FONT> of <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT
STYLE="white-space:nowrap">HPV-18</FONT> using the cobas<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HPV test from ThinPrep samples, at approximately 6 months following <FONT STYLE="white-space:nowrap">VGX-3100</FONT> or placebo
administration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Based upon blinded aggregate data, the overall safety findings have been consistent with previously reported trials and
considered generally safe and well tolerated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Data will continue to be collected until the end of the trial (week 88). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conference Call / Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss the data from REVEAL 1, the Phase 3
trial of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> in <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18</FONT> caused cervical HSIL and its full-year and fourth quarter 2020 earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The live webcast and a replay may be accessed by visiting INOVIO&#146;s website at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/events-and-presentations/default.aspx.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About High Grade
Cervical Dysplasia (Cervical HSIL) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Cervical HSIL is the <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> condition of the cervix that
immediately precedes the development of invasive cervical cancer. Cervical HSIL is caused by persistent infection with high <FONT STYLE="white-space:nowrap">risk-HPV,</FONT> including <FONT STYLE="white-space:nowrap">HPV-16</FONT> and <FONT
STYLE="white-space:nowrap">HPV-18,</FONT> which collectively confer the highest risk for cervical HSIL development and cervical cancer development. Estimates of the incidence rate of cervical HSIL over recent years have indicated that up to 195,000
cases are diagnosed in the U.S. annually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About <FONT STYLE="white-space:nowrap">VGX-3100</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap">VGX-3100</FONT> is a DNA medicine in clinical trials for the treatment of three <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-/18-related</FONT></FONT></FONT> disease states &#150; cervical dysplasia, vulvar dysplasia and anal dysplasia. The cervical dysplasia program is in late Phase 3 clinical trials
(REVEAL 1 and REVEAL 2). <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is designed to utilize the patient&#146;s own immune system to clear <FONT STYLE="white-space:nowrap">HPV-16/18</FONT> virus and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-/18-associated</FONT></FONT></FONT> high-grade precancerous lesions with the aim of reducing the risk of cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About INOVIO&#146;s DNA Medicines Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO has 15 DNA
medicine clinical programs currently in development focused on <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, cancer, and infectious diseases, including coronaviruses associated with <FONT STYLE="white-space:nowrap">COVID-19</FONT>
and MERS for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA medicines are composed of optimized DNA plasmids, which are small circles of
double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO&#146;s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO&#146;s proprietary hand-held
smart device called CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of
other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated
immune responses. Administration with the CELLECTRA device is designed to ensure that the DNA medicine is efficiently delivered directly into the body&#146;s cells, where it can go to work to drive an immune response. INOVIO&#146;s DNA medicines do
not interfere with or change in any way an individual&#146;s own DNA. The advantages of INOVIO&#146;s DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in
storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">With more than
3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global
health needs. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious
diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and
tolerable immune response. INOVIO&#146;s lead immunotherapy candidate, <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk
<FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18</FONT> in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in
development are programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers and a rare <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease, recurrent respiratory papillomatosis (RRP); <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">non-HPV-related</FONT></FONT> cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with
<FONT STYLE="white-space:nowrap">COVID-19</FONT> diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill<U></U>&nbsp;&amp; Melinda Gates Foundation, Coalition for
Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial
Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker
Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient
of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information, visit<U></U>&nbsp;www.inovio.com<U>.</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>CONTACTS:&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Investors: Ben Matone, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Media: Jeff Richardson, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>* * * * </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> cervical high-grade squamous intraepithelial lesions, plans to present clinical data at an upcoming
scientific meeting, the advantages and potential benefits of our DNA medicines platform, as well as <FONT STYLE="white-space:nowrap">VGX-3100</FONT> and our other product candidates, and our expectations regarding our research and development
programs, including our plans for a collaboration with QIAGEN to develop an <FONT STYLE="white-space:nowrap">in-vitro</FONT> diagnostic to guide clinical decision making for the use of <FONT STYLE="white-space:nowrap">VGX-3100.</FONT> Actual events
or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in preclinical studies, clinical trials, product development programs and commercialization activities and outcomes,
our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine product candidates, the ability of our collaborators to attain development and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including
alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide
us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can
finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December<U></U>&nbsp;31, 2020 and other filings we make from time to
time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of
regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update
or revise these statements, except as may be required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ino-20210301.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 3/2/2021 2:13:07 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:ino="http://www.inovio.com/20210301"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inovio.com/20210301"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210301_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210301_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ino-20210301_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 3/2/2021 2:13:07 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ino-20210301_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 3/2/2021 2:13:07 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ino-20210301.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g320584g0302005608426.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320584g0302005608426.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !P 5X# 2(  A$! Q$!_\0
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MFM>CZ=_R#+3_ *XI_P"@B@"S116#K^M/97=AIEK)'%>7[E5ED&5B4=6QW/(
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MG^T%3R, XC7^1_"@#I_ W@]-)M4U&^B4W\HRBL/]0OI_O>I_"NUHHH ****
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M_4O_ +IKROX5_P#(<OO^O8?^A"O5)?\ 4O\ [IKROX5_\AR^_P"O8?\ H0H
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M6?$O2GLM5M=:MLKYV%=A_#(O*G\0/_':]!T'54UK1+6_3&94^<#^%QPP_/-
M&A)(D4;22,%1 69CT %>/:8C>-/B US(I-L)/.8$<").%7\>/S-=E\1M9_L[
MP_\ 8XWQ/>GR^.H0?>/\A^--^&^C_8- -](N)KT[QD=(Q]W\^3^- '9T444
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M=_R*B?\ 7TG\FJ[X _Y$JP_[:?\ H;52^)__ "*B?]?2?R:KOP__ .1*L/\
MMI_Z&U $OCG_ )$O4_\ KF/_ $(5C_"W_D7+K_K[;_T%:V/'/_(EZG_US'_H
M0K'^%G_(N77_ %]M_P"@K0!W-%%% !1110!3U33+;6-.FL;M-T4@[=5/8CW%
M>26EQJ/P]\3O#.K26[X\P 8$\?9E]Q_B*]GK#\4^'(/$>EF%L)<QY:"7'W6]
M#['O0!POQ.NX+Y='NK:198)89&1UZ$96O3=._P"09:?]<4_]!%?/M^MW:%M/
MO-Z-;,P\ICD(3UQ]< U]!:=_R#+3_KBG_H(H LUQ7B.TN(?&.GW:3+;VE["U
MG-<;>8SR>#_"6' /:NUJ&YM8+VVDMKF))89%VNCC((JZ<^1W(G'F5CE RB*W
MN[.V58D/V?1K4CAF(.9B/3&3G^Z">K5QVE^(I_#VNZSIFD#^T9+RZ5;=Y#A?
M.Z,S?4_TKL;SX?Q74\9&OZU%!&"%B6YSM4XRH8C(7@<>U4M1\!6NC6]I?^';
M3==6,OGM&[%FN.<G)/5N/\\5U0G2^%N]S"<9K5="*S@\0WEQ9O>>([CS)WG7
MRK545%:/C ./F!([UG:CXSU_2-&EMM0C6:2ZLUDMKN(8*%QT;MD?-^([UK:+
MK6FE])9[E+9XI;M[F*X<(T+.2V&SCUZUBV.C'QG>Z3$$E_L?2U N;ELJMXP9
MBJ)W91G[W3DU2M?WUHO+U%:3^%Z_\,:/AVSBBT2QLXIFC68AH9VP6MKU1RI]
MF'0=QD=Q4/BYI;CPS?+:HB7>H2"SN+!CG;=9&'08YR.3ZC![&M.;X96B2/\
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A'(!&<'Z5H57L;*WTVPM[&TB$5O;QK%$@Z*JC %6* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g320584g0302010349590.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g320584g0302010349590.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ 4P# 2(  A$! Q$!_\0
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MY'R$UG'"7>]TM^^AI+%66UF_NU->]\6>(9[VSAMK"UMK>_CW6[7+Y$@_ND]
M2.U97AZ'Q*([[PQ#'9(+63=)]H&_8'Y&T=Q_C6M8V]@Z7OA/49U:U0?:=.N0
MXR(R>Q]5/Z5:\#6=Z]_JFK7L@E\S9;13 8\Y8\C?^/%;.480E9+I\^S^ZYDH
MRG-7;_K?\;&SX8\,6WANR:.-S+<2G,LI'7V [#VK=HHKSISE.7-+<[XQ4%RQ
MV"O+O&$$GAOQE:ZW;+B.9O,('=APX_$5ZC6!XQT?^V?#EQ$BYGB'FQ?[P[?B
M,BI*-=;VW;3Q?"0?9S%YN_\ V<9S7FOA2%_$_C:YUFX4F&!O, /8]$'X#G\*
MR5\4NO@5M%W-YWF[ ?\ ICUQ^?'TKT;P5H_]D>'(%=<3S_OI?7)Z#\!B@#HJ
M*** "O,H?^2QO_OG_P!%5Z;7F4/_ "6-_P#?/_HJ@#TVO-?&MG/H/B6U\1V:
M_*[#S,=-XXP?]X5Z55;4+"WU.QEL[I \,HP1Z>X]Z &Z9J-OJVGPWML^Z.1<
M^X/<'W%6Z\I4ZQ\/-38%6N-,E;_@+>_LU=]I'B;2]:B#6URHDQS$YPP_"@#8
MHHHH *1W6-&=V"JHR23P!5._U:PTR$RWEU'$H[%N3^%>=ZQXDU'QA=?V3HD,
MBVS'#MT+#W/84 -GD;QUXXCCBR=.M>_;8#R?^!'BO4@   !@#H*QO#7AZ#P[
MIH@3#SO\TTN/O'_ 5M4 %%%% !1110!S6E>$DTOQ)=:P+II&GW_NRN,;F!Z_
MA72UCR^*-'AGDA>['F1.4<!2<$=15K3]7L-4WBSN4D9/O*.H_"@#(OO"27OB
MNWUPW3*T+(?*V\';[UTM9-WXETJSN&MWN-\J_>6)"Y7ZXZ5/:ZUI]Y:2W-O<
MJ\<(+28ZH!SR.HH OT5';SQ75O'<0.'BE4.C#H0>E066I6>H^=]DG67R9#')
MM/W6':@"W15&[UBPL9)4N+A4:*(32 _PH3M!_.J7_"6:-_S]_P#CA_PH 9XE
M\+6OB.",2.89XC\DJC)QW!]J=X8\.+X;LY[=;@S>;)YF2N,< ?TJQ-XATR"U
MM[B2Y"QW&?*.T_-CKQ42^*M%9U7[:J[C@%P0/S- &S1U&#5=KZV2Y:W:4"58
M?/*_[&<9I+#4+74[1;JSF6:%NC*: ,JX\&>'[JY,\NFQ;R<G:2 ?P%5-:\*G
MS+/4-!$5I?V/$:@821.Z-_C71->0+?)9&0"X>,R*G<J" 3^HJE>^(=-L+C[/
M-<9F')CC4NP^H'2M8UJB=[F3HP:V.,6TU+_A"=0T:;2;O^T+N:60[5R@9GW
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M4AXMT5E#+>9!&00AYH VZYI/"2)XO;7_ +4VXL3Y6WC[NWK6@?$6EK8B\:Y
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M/;WR2HMD=CW41ZN\>2A_7]*M^)-*N=3T^/[#(D5];RB6"1N@/0_H30!S=_\
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M."==DTOG>8=O?:,#GZUT<4:PPI$OW44*/H* %1%C144851@#VIU%% !1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d320584d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20210301.xsd" xlink:type="simple"/>
    <context id="duration_2021-03-01_to_2021-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-03-01_to_2021-03-01">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-03-01_to_2021-03-01"
      id="Hidden_dei_EntityCentralIndexKey">0001055726</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-03-01_to_2021-03-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-03-01_to_2021-03-01">2021-03-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-03-01_to_2021-03-01">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-03-01_to_2021-03-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-03-01_to_2021-03-01">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-03-01_to_2021-03-01">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-03-01_to_2021-03-01">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-03-01_to_2021-03-01">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-03-01_to_2021-03-01">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-03-01_to_2021-03-01">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-03-01_to_2021-03-01">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-03-01_to_2021-03-01">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-03-01_to_2021-03-01">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-03-01_to_2021-03-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-03-01_to_2021-03-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-03-01_to_2021-03-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-03-01_to_2021-03-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-03-01_to_2021-03-01">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-03-01_to_2021-03-01">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-03-01_to_2021-03-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-03-01_to_2021-03-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140538826686792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  01,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MO(-A4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "\@V%2[HEDV^\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "\@V%2F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( +R#85)A5U<75@0  .L0   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "\@V%2@ZFE ]0!
M   R!@  #0              @ &:#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( +R#85*7BKL<P    !,"   +              "  9D.  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( +R#85(<.&7J/P$  #P"   /              "
M 8(/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "\@V%2)!Z;HJT   #X
M 0  &@              @ 'N$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "\@V%299!YDAD!  #/ P  $P              @ '3
L$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   =$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d320584d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d320584d8k.htm">d320584d8k.htm</File>
    <File>d320584dex991.htm</File>
    <File>d320584dex992.htm</File>
    <File>ino-20210301.xsd</File>
    <File>ino-20210301_lab.xml</File>
    <File>ino-20210301_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d320584d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d320584d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20210301_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20210301_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20210301.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20210301",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d320584d8k.htm",
      "contextRef": "duration_2021-03-01_to_2021-03-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d320584d8k.htm",
      "contextRef": "duration_2021-03-01_to_2021-03-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.inovio.com//20210301/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-21-063569-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-063569-xbrl.zip
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MO69W/3C6,X'3;39^Z;1ZK6:7U-N7I/E[XV.]_:%)&M>?/K6ZW=9U^U$P.H>
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M]KEZ= RN+X3?IW"B&N@/8:Z\+9?/EQ7&-L=LT8\B\X=.'BV2%XJ)<K4$'X"
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M0;<"HW6DAV\ABE74!Q8 @?C0!,HO,GJ&_%1P"@C)SD4LQZE!A+#S8/I*)30
MC8&$C$60IXX-I'.@QSLZ)FH(!H31MWT&%B2H<2\][P'WF9<<D,$S:,=0*&8H
M?%X[GNUH]!TC"NDH/I0#TE9VK=4$=CR]9G$/%@%14?]/V 'J>83"Y[3/?3#4
MXGU0352\OV- C4R0Q+,X6G_L/$!*F57_-%)K,2G7BTN(U/H*B\0Z?RI<S:^V
M 5N+IL[QU#,940_L.:. L2,=Z&0G>%';D)88'*-M!]:5G]2\(D;F+I00'R:.
M0-D@O:K(!<,MP<TQAG!8:&Z_LK'A2BS# L\-5@3N 70GEV+=.;S/SU)8O-B;
M$99GC\W\O6IKZ_QM 5^?]-4JZ]O(C^GP_26YY,KUA8HD^W+T<D9V[* =I_I0
MBI%1E2*X%=@ >AUZEH@+/(%' #X4ZD^\WJ6-Y^.!_B$N* ANN'>KYOGUP^_Y
MDHTETDD-92(J-!"AQ@0FSCT$U.=O)<H) -E%S2=%!#X[DW<&"F^"+[%3G,+2
MD8IEZ-:E/][\FK=/TX4!Y"*LO=NHL]2NG-/Y7"TK_4$D ZY2K1][E'-ZWXFU
M!E=)67"!]!84,/KU-(W%+%L6LQ46)SZP-IZ7WE^/ GS5/:^Z9[/NJ7S-NF?F
M#IH;5B@S5=9"5SLHH0Q$SE/7+1R&X'8H7, X3%*\D'SP8BRD3[N4&:RI<(@;
M*Z5G+C/8N40@I=T5-T!V(M$=,K<D?7-L_#;>?-\7[N>#9ST3(K[H2U*LM47A
M(:GKM0FJ[Q:=Y)(I5_(P?3? C(9G3+-"-BP39'J3"%M6(#C3#&8,2@= HO/,
M[VU9%MDKBVHPD/%4E!5G-BF)W_CKE1SKY*SLL7&E8A>&>F3*]L"XZ,0FW;&Q
M/KR5=GQBO[7:U[^VKI/WJRGR/HY7_3N)5V$XBM1!!6RU9O_#J,PW R\U9V?*
M)(D_%E(C\:)(UQ[;=T0BSO.3B/,H$JG'7AU@XT9@LNN.I4<;>W>=YJ_-^A6!
M<73JW=WP.Z&!!GK&N6MBN00U2:Z=W;EI-!'=PJVC+MOU/+YN>DJ&X&21%A:L
M&A>#@H.5^H6]K%_X<>87WF3]PD;J%UY._<+&,_F%";NDHU^Y)E>SK?*3,DU#
MP+<FF6?N74KJ&BH'!C$.%"-'&*WW,/")_G?B1+>,FB7X1P2(E[QC$I/_,T4X
MM9/QXRS/:/3C=YUL?-'W771;']KUWB^=9G?#JQ;CMY@^-I26?2EL7%[P5\1E
MXF'MFJ)849?@1?XD#51E(C^X3!_\<M@M-(CX]8Q]-J3^ .463F2"'$D'#$Y$
M&!PQT\'A#(6$C7F;H@5?KW.WTIU;N(ERDGIC^SAX&^O(RWO-N*D@_?"@G<SY
MGLMV^W.(_ W[WK=8\+EGGJG-TO9(46Q*W7RL=S[5&\U?>JU&_:I[3%KM1F&I
MUF]_)8]LN4G+F_9E-?]4?5_(?$C/$=_O7%UAV'Z%-%;[:5)]NLGWJT;?4E6U
MIVHLJB*Y8>AK_@RJ[]GKT+\=,?2$,V?/Y_5LOJR9&T/.!IEHR[5Y7Y?<U?VX
M*)H_Y75A_M!7[?]02P,$%     @ O(-A4CRA\W'M/0  *N(! !$   !D,S(P
M-3@T9&5X.3DQ+FAT;>U]:5<;2;+H=\[A/^1A[#GP7DJHM O;G">6MNG&P "V
M[]QO)2DEU;A4I:E%F/[U+R(RLS8)$&(K3,W2C:1:,B-C7S]^N?QZO/OQRV'W
M8'=][>/ET>7QX>[A_Y0ZG;+Q<5M^A.^WU07LX][IP;_9WN?]T^/3\T\;/[X<
M71YNX ]L?0VNVQ=.(+S=CP='W]G%Y;^/#S]M7%F#8+S3+C<L9X.9MC5R/FW8
M8AC071_/]&43TQM93BEPISN5:?"!J<\]-PC<B?QJZ#I!R;?^%CM&_'EH3BS[
M>J=[?M0]WF#=XZ//)Y\V/&LTAA=\W-L]_#6V>E; <#_LX_;>[L?ML]W$:Q//
MK,(S,ZN86\3&[C^=GC_]@$^![=ZT^OG[],KZ!"#<.\'KZ.MG=G&^_VEC5*M6
M&NWZJ%*K5"N51K/2KE>;Y?],1WCGY:>-X]//IQ)BZ?4G7DP;>!C<].H <$<G
MI]^/3MFYF+I>X+,_W- +QNQ?H>G!%:P*JXS >0L@'FTY76? /OYQ>G(9H=78
M"D3)GYI]L>.X5YXYW=C]MS"]TJ$S^+B-5^ZR/RS'=/J6:<,V_-"&;=RQY.:C
M0M"9"3]P/;9OVC:[= ?F-3,#5M^I5=C95W9XN0@?'_<\_Q/Z@36\WM@]._[W
MU]-OEU_6U[X>'EX>G7SF[*S+_OD/HU'YP+Z:7G\L\=K@>+2&_D4AP>9)]^*@
M^Z\=^+C%F<EZEAN(_MAQ;7=TS?KN9&HZU[",?NB+ 7,=!J=A#>QKUO,L!U8_
M8H&+&_DI C;U1-_R!?PX$#XP [CAX*3+)F)@]2U'^'AIX D E E'/O7P37"7
M<*>V8$//G3#+&<)7EAOZ; !/,GWA<]:'@Q8>IYLDGJROW8(I7\Z^ETS?=P$Y
M A'A2_RX@$[+(^2'%0XC1/(4(@WA7(.Q8/]5!"&< >Y$],6D)SP)S)J$9J6L
MX A K3<_^  )QQR)"6 *N[( -<:N#[MEMC43 $S8G2=@,[ E^ WW<R5Z?1,O
M4<@S+4_*[!"^$9[#+@*XQ/0&[-*:"+GN]36 (>P%CL-?L'0%UYDU$/#6D7"$
M![_V0A_![[-P.@"8< !SWPX'<'@[=Q,>H&O)AMLU(,5P:/7-/IRQ&9CRU,X/
MOQ]VCYGQ =YY-@8HLQKKPSUPG0T'C@MTAW>_Z?OG_RG5C$KE@WZ5B7L9P=[\
M]36Y].AL%&)JL!^=P"ET+P_5ZZO;M;M?MP_G=E R.OIM,[./6)I=.8+4 M .
MQ$S8[I2.U@\\6,P(L6@$YT-4 (MRQ-7JKS4' ]RI?E8_] !5@O4U?/\P#$)/
M,+H5;H!U.; B@"F@5!\Q9?/[Z?[6!UIK?.P*9$"SN/XT)4YM,P!8 K)=PLL(
M/2-4I(< ?=A )A/X?P\6U^_#VH *>M=L9OE6@,M,8S[<#M_#I;#FC]]V[X3#
MG1>,@V"ZL[UM>67+ 8QVRW#FVW (L/42K+$$W,:'#R:P"\??'HBA"210-OWI
M+P7:Z%_?=LNWR=;VRKPX(4RE$%U?TU+47$6HD>C] @J.C4J.?[M2T[RG3L-0
M!^SN'1_J1^V=GA\<GI= W3ONGET<[N@_%NPT"XP-)F_^M%'98/N'Q\=GW8,#
M$#W1YXNS[K[^_./HX/++IPV@[/<;<A7G0$'7P/,_L8TIL,M2#X3"SY+E^,"W
M=LR9:PW4A0?ZYL;[>"N7!YD?:^\WV'<E%@$4D8B4JB@B:&?1;4;FM@4O2#XH
M?2T>2482:[BR]*FPFY'K5A#OGCH+Q#?7@MMT'#<$ZA\ NP#I 7KPA$2P!2^[
M)O3S!;"' 7Z*>#:(LJEK(?,P)RZ0,(HA,3/MT.S98GW-#WO_ ?D;BT#-V=DF
M8#I0]3D2$V(E/-^=P%(!R>F'0_T#/0Q)DE@^_?9=_W8G/2@!H,E!WF[JVYVY
ME]FP6,\%02[?J%=-.@8Q:EC#OO!FQ,Z_7!S)VX_U[5N2Q9?7UR['EJ_X/?SA
M CN&.X,K%_X<N<CKIM;,#4R;@_JC=\[9P T!;*4>" SX- 'V8Y6DDLB1P?9%
MSRW!$< 2;1NOU[*17N0KP >:X_OF4 37J)_8P+Y[EFT%\ARCT[N/$-4PC%2N
M)32G.Q^.JI71W#;:\PJ6?E]?@WL,+*PT\DS01'S0I":HTP'F>::86K!=&V%M
M@YH(S)MMPMD<;[$PEGYI\0YJ ""V" "7U]>0O1SN7YYW/UY\6\ 6VXWW']A,
M> &NHD1&Z8ZD;A#60-QPTRYKG%V<H42W^D**!B)Z^,<Y_@.99,%SWR3//0(N
M8GF@!?TWMH9CGHMH:0NT&H2#1*UY3+U281'OM!Q"8:6) A<>Z<OP:ZVIKJ\I
MEGITHMD1O4+QJ)-3_6VIWH:G*TX:\4*I,\IO+_67Q+^0"6;8I.(?6PGM.*WD
M%C10T$""!B2R@R#,V"1HWV1LD&#LN>%HG)5E%K#O/N$\W&-?L[[E]4-;_H[&
M$X!<$\1CR*6+[OE%:=_]7JIFI-',\D*4YVI1DQ"(!H3)T+)%^OVW/!S 030X
M9["!:%9&(6[+$;^"DC2]4!GA<)!W/1E$7(G@.6>"PK,M--[ K!J[0++2GP+\
M)[3!P'<#8"A M@!8;>SW1(#<2OE44!DR1PCE@/;X$][HT(*560EWA@Y]N\0R
MEP'_8N@K+"G82\%>4B)6^]*T2FRPJ1!>R0.%3%R!=(VD4^QC0C26DKGOCEU/
MB5TV-5'1LZ;$C,S!!.Y#WQD\XPJTS&682Y:\KTS0-T&OM_PQ/ 6$.3I(CM$%
M&6AU]./1[N&^6N)7Y5+YN'VT6^!Y@><I/#]Q9PK/E4Q5/BOTI,_01V>#V@CV
MT@S]C $SV@RL\F ,!M'IA='>2J _>O <N,=&';1G.=+@S?A6[\3S1KUB1,[5
M91Q4>%.G8FC&CN20?'^"QFYYR-E!R8@?0#$[T%&/K5Y@7KL/,.),$FZP:;!$
MP7(FS?=$A)Y;.G7Z,GZQ>7%RNB7=:EW'"0%87X5 +:3,D'!-9\$YD&,$V4WH
M3$0POK;1RF6?;<OMV:8/&&"RKVCJH_M4@*9-7KK-SWM?MX ;!1;Z)[4-(,\'
M.8K1*G?4X7*0Z59_+&U<P <V!)(!@Q]D,ACK8POC2L3\E.O@1O&)L=N#H^_P
M685FU]<8_>_C5!)HVLTI)G.8C%\E*+@G8$] P?:5>>UC1/+CEW-V<?2_<#2U
M#?U(B@[O_*-#_TES!TU1^X<GEX?G^0L=1R&S Z\LF<6?9?8GZ%?3,?O+FO",
M1_L,#@<XFB-=XON'IYSYIC7@&$&KMS[\$&QLSO ? QFI&(2@><TP1B%=P=J$
M-/N>ZX,6&GHW..$3 1F&>IZ%]AJ\-A%R\(G6 *U@YV-ZU)>S[[0N5^,ZQ4K,
M":#+#Y%@- )^#SV30G617(U<2CIP!$\VF0W/PU#> AX#RUQ"4\SR&'@JT(4B
M5 :TN(@4&5)5Q"J!,#%D!@8$"'D3-56@%Y'U=B( (M_D#2$G,H3OZR[+^%#7
MUQ).U-M\IY'Y3] 'LH9%A%(_#P=(U^9@ACK$_5=D^@G=)XD_^%0@6^ D 7HO
M(X@QP'P,3CNBC(C:_L!NB8H_9B!:DH62=![ #3#Y;R&#DN84D#T<R+T MH.&
M9B'8KEQ -P(/69KT\\AV>W!^]XZD@1(X$!.KKPF.A(/E#&!]WC5Q77BA:?OP
MMC[:/K88C&+3%D/!@#'(="TG1"74M6VSIWW+9#RY+@;[Y!> V]I<2] IQPAP
M. 3C-\3XN#02@:5[5B_$V\KL"-!'K@(,1D],1(0ERB =X/G&+P52I2P-^!6Q
M7H$W$.9$2F-'/5M&XA$5UM<4!#%PC;*%LQ'&*X>AG8B?ZFWZX72J]&E\/BK4
M8,/Z,MP.Q.;\U/<APFNO5DKOAG7(I:D@[ )"A'=:'AL+>ZIEH_:L#S'4E;)6
M]3D2*=FN^Q.?<(5Q<-B@'U(H$M9D7VM_'#X&%K"^EO6YJ5=)&HY<>C(V(GXJ
MD&G*).B)B)L@4%08(Q+EBJ"D[)C_YS,%&5.9.K!IR??9MZGT&-R>>;)Z&LRN
M]"HB"SI"3PH((H')(,)?(HM@<5+&@4K*H".1#XUUMRAJ]!1I2&HS2ZW;$_;"
M12<7^"3 OENIU\)B1R].1[LX^Q[:,U-ES70=&?\Z?C+DF!,&\U%*2KM9(E:I
MQ>SZVFUR=CY$J3S9EY'>C<XP%Y"I-!!#"Y.1)NX 5"NRZLF#AMJ-#H]M3HXN
M+T&#=Z?DIX2?-D\^&9W:EM+-$$G)3%"O)]-'KY4,M3*0IUR2WECT,_ 0TNO!
M/A@C<A-S!$N&G*N2Q]#I2+U+@-I!CY]9GKP:.*HP/>)2R\0 99@N8>AM+Z,*
MT5WMZ*X U"[QD]6:7.Y)>!C:!&,!EP +G\)Y@9P@ZZ9:*[?>L\V:L6W4C*W8
M^M%AV!'(MRE'@\X/P18RRC6XNK7=K$;7JG IB"Z\E&U./U7*E6KU S.JY?I[
M$*%#G3H%-\1KX:S3>+]_M,,JY3JO5LN-+5PMO /4(DO,I+L9CM,G0S*A7&/<
MKXOG>5N,_ I>J9XD74&X4L23!)H0PH' 2-^UP\RMS 'W$W'H8\0[!S1_E)&6
M[X>@J.BSEY@%AT&!5L0!- 7U^7/6N_W!I@V*'V?]^[U>LHG!%ED5"U\L'UQ^
M+EWR%BI>1+P+:+=:,3*T&X?N8S*6"5PVJIX )'-F6K8.O</G%'U+>T"N I5+
M],OC6;EAD+W0OYO:'-<IQ514UF0'^_:$1#Q!BA'H.^-XN9L^)D#=2&"8N) F
M*/G+%JB=L8698F$32\9W4CM80/*)Y)")LML6LCIB!T"(FAVTEV$'AF0'M2P[
M8"ENT/F UR[##>Z$?HGXA5&N;O'([TM.&5P^:#:PVYAM@**9L,KG^,;M["+-
M+4#G[XMI0,+K3BIFF\#\VH^TW2:OUH$])A$-K4<?TR]P-0H/UM?2J"R9&2Y&
M'3]!*$%)8'I(H,&F/38 HAA(/$3L&GCF%7KQ0]*NI[!C3%B]OND"[;]7)I?P
M/+1=;GB8ZP>ES U3L"'D]38Y7(9+N"R&8.6Y5Z5P&B4*R^>3<6ETM/('V&NB
M]Q5.#-@21=@B$\D3\H4RP7GE-X; "4"KGQ"34T<#R';W P$C2II+JF=BVJAI
M7_N6+].0R=[L$4F3VW+ PFGDV]%6% HSQ=X+O^*J4DMS;\>-&5Z$1+[P*+<=
M3$[@?<#B*9N5T&A"B>+I[^E!OK"'*"E<>Z8<"J =X@_ @- ]Z9%NC8<+*Z,_
M0<W%(#1J 7B)'\AL=-173<^V@$S3!KI_:W;L(PKU2%7'#:L/57*61?4"R 60
MDGSE<'&&EC>1GIQ%^7%<!O7=D8#]T.>5$^8BSJ@L%Z(;[2;!=4FZ3>7Y1!M"
M#BK7)Q6IT$MH$5+,^S)Y/8[QR.=I04I.T P_H[..X 2T'$?O9?Y14ISK2@00
M,5-:G^2XZ 5.K--R4 ?P4;TWF=_': 7*M81,A]=< YX\%TXDHL'DS^#RL'7A
M252F ?S>(N^Z]O',N; ' @ K84<;B7(>[^%L]<?N%7%?(+<PRF)]<(+$W7F3
MZVM8/$.%+L0@(H,=L*Q1 ?7(,' I5;"8X%\1#OK6K\7H!.J+].E%3$A:QNY4
M."50<87-[]X7*@2V*)G>),HFE241*$T4J%9)2.T)9&&V79*D'"AM"5>*ZX?5
MRMH8%_]:+L;X6&=4NNV08HM:G<ZSF4- )7^:3HCZIDQ(3"3)RN.8)Y0Y J%
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M0# E_<G#/!=4^:6V<F$ZL/4RZPX&%NY/%[*0\M,3NF@KBA'"<9+?2Z6'Q\G
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MU(..A(?@:!U,7147;;#-H^^X\[],1_PTV6'H85$42&/.R \&]^ *HC?N [A
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M,NM(]F73I)3@$DOU3%-?(=,E"*$P"+"/L 7RRPEV2OK+E?A:]^("6)CF8(^
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MS2M&B]>,O/MW.PU>;;1XNU7T4+ZYA[)P@/G:<@3[8&(YEA_(@$D^J*+6 JJ
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M-&N\M51VW$NBK,&-3A6H+._IAH5^^#ID>Z']%! J],/E?>M9Z7?DN#/+73P
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M-XC$ZS?'*3(F\(/(@ 7JM?[P_'S8O[WNG=S\OL9+.-A_=<P6(LEP%4UR9XY
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M)#UE* [LLIE+F8(?2#C$>73?YF+@D*95D/:V[?%X!Y;+@V4J4<:!6<D+GI!
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M"8 X$H$VVS'PG\8Y<PR8^T);(Y1IC,Z#.P]>"FA.4IA(;7"H9.;@CDG8T-D
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MRK>C@4 JD&VPH'M9%*8T*OE)?7R%;::9B/@J9-; X8^'R;'26\CJH%;"U#S
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M05B)V^* KF7D[R_7WWR11F<. .#KEE>UTA;:\KU6A6^J/>%WN[C/6NR.XFR
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MV$:YB/92<XL%]AW<]1G[S[Y1BB5_ 5!+ 0(4 Q0    ( +R#85(BZ@ HOQ
M (5O   .              "  0    !D,S(P-3@T9#AK+FAT;5!+ 0(4 Q0
M   ( +R#85(\H?-Q[3T  "KB 0 1              "  >L0  !D,S(P-3@T
M9&5X.3DQ+FAT;5!+ 0(4 Q0    ( +R#85)2 KHFF!T  %-O   1
M      "  0=/  !D,S(P-3@T9&5X.3DR+FAT;5!+ 0(4 Q0    ( +R#85(T
M_ :B7P,  !P,   0              "  <YL  !I;F\M,C R,3 S,#$N>'-D
M4$L! A0#%     @ O(-A4K,#[*>!!@  2$<  !0              ( !6W
M &EN;RTR,#(Q,#,P,5]L86(N>&UL4$L! A0#%     @ O(-A4@N/32S#!
MR2P  !0              ( !#G<  &EN;RTR,#(Q,#,P,5]P<F4N>&UL4$L%
3!@     &  8 ? $   -\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
